JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

JNJ

167.77

-0.47%↓

NVS

117.04

+0.03%↑

ABT

128.88

+1.5%↑

MDT

92.19

-0.3%↓

ELV.US

289.61

-0.49%↓

Search

Minerva Neurosciences Inc

Deschisă

1.88 -5.53

Rezumat

Modificarea prețului

24h

Curent

Minim

1.81

Maxim

2.01

Indicatori cheie

By Trading Economics

P/E

Medie Sector

2.197

38.156

EPS

-0.5

Angajați

8

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

2.6M

11M

Deschiderea anterioară

7.41

Închiderea anterioară

1.88

Minerva Neurosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 iul. 2025, 23:57 UTC

Achiziții, Fuziuni, Preluări

EQT: To Spend Y407.82B for Tender Offer

29 iul. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

EQT: Tender Offer Price Is Y5,700 a Share

29 iul. 2025, 23:54 UTC

Achiziții, Fuziuni, Preluări

EQT To Start Tender Offer for Fujitec

29 iul. 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 iul. 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 iul. 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 iul. 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 iul. 2025, 22:44 UTC

Achiziții, Fuziuni, Preluări

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 iul. 2025, 22:41 UTC

Achiziții, Fuziuni, Preluări

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 iul. 2025, 22:41 UTC

Achiziții, Fuziuni, Preluări

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 iul. 2025, 22:35 UTC

Câștiguri

IGO Maintains Nova Life of Mine Production Guidance

29 iul. 2025, 22:35 UTC

Câștiguri

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 iul. 2025, 22:35 UTC

Câștiguri

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 iul. 2025, 22:34 UTC

Câștiguri

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 iul. 2025, 22:34 UTC

Câștiguri

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 iul. 2025, 22:34 UTC

Market Talk
Câștiguri

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 iul. 2025, 22:33 UTC

Câștiguri

IGO Had A$279.7 Million of Cash at End-June

29 iul. 2025, 22:33 UTC

Câștiguri

IGO 4Q Underlying Free Cash A$2.4 Million

29 iul. 2025, 22:33 UTC

Câștiguri

IGO FY Sales Revenue A$512.5 Million

29 iul. 2025, 22:33 UTC

Câștiguri

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 iul. 2025, 22:32 UTC

Câștiguri

IGO FY Nickel Production 17,173 Tons

29 iul. 2025, 22:32 UTC

Câștiguri

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 iul. 2025, 22:32 UTC

Câștiguri

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 iul. 2025, 22:31 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

29 iul. 2025, 22:31 UTC

Market Talk
Câștiguri

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 iul. 2025, 22:31 UTC

Câștiguri

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 iul. 2025, 22:31 UTC

Câștiguri

IGO FY Spodumene Production 1.48 Million Tons

29 iul. 2025, 22:30 UTC

Câștiguri

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 iul. 2025, 22:30 UTC

Câștiguri

IGO 4Q Underlying Ebitda A$62 Million

29 iul. 2025, 22:22 UTC

Câștiguri

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparație

Modificare preț

Minerva Neurosciences Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

$

Despre Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.